Patents Assigned to Bayer Schering Pharma Aktiengesellschaft
  • 2-(3-phenyl-2-piperazinyl-3,4-dihydroquinazolin-4-yl)acetic acids as antiviral agents, especially against cytomegaloviruses
    Patent number: 7960387
    Abstract: The invention relates to dihydroquinazolines and methods for the production thereof, the use thereof in the treatment and/or prophylaxis of diseases, in addition to the use thereof in the production of medicaments in the treatment and/or prophylaxis of diseases, especially for use as anti-viral agents, especially against cytomegalo viruses.
    Type: Grant
    Filed: January 29, 2004
    Date of Patent: June 14, 2011
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Tobias Wunberg, Judith Baumeister, Ulrich Betz, Mario Jeske, Gerald Kleymann, Thomas Lampe, Susanne Nikolic, Jürgen Reefschläger, Rudolf Schohe-Loop, Frank Süβmeier, Holger Zimmermann, Rolf Grosser, Kerstin Henninger, Guy Hewlett, Jörg Keldenich, Thomas Krämer, Peter Nell, Tse-I Lin
  • COMPOUNDS AND PROCESSES FOR PRODUCTION OF RADIOPHARMACEUTICALS
    Publication number: 20110137063
    Abstract: The present invention relates to novel perfluorinated precursors for the production of F-18 labeled radiotracers for Positron Emission Tomography (PET) and processes for radiolabeling and purification using these precursors. The invention also comprises radiopharmaceutical kits using these precursors and processes.
    Type: Application
    Filed: June 24, 2009
    Publication date: June 9, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Ananth Srinivasan, Mathias Berndt, Keith Graham, Matthias Friebe, Heribert Schmitt-Willich
  • IDENTIFICATION OF NEW SPLICE-VARIANTS OF G-PROTEIN COUPLED RECEPTOR EP3 AND USES THEREOF
    Publication number: 20110130347
    Abstract: The present invention is directed to a polynucleotide sequence of the novel G-Protein Coupled Receptors EP3-11 OR EP3-12. The present invention provides polynucleotide sequences comprising the nucleic acid sequence SEQ ID NO: 20 or SEQ ID NO: 21 or nucleic acid sequences that hybridize to SEQ ID NO: 20 or SEQ ID NO: 21 or its complimentary strand having at least 40% sequence identity. The invention also provides the human EP3-11 or EP3-12 as targets for the identification of compounds useful for the treatment and prevention of cardiovascular diseases, inflammation, reproduction disorders and cancer as a result of relative quantification of the mRNA distribution in different human tissues by expression profiling. The invention also provides assays for the identification of compounds modulating EP3-11 or EP3-12.
    Type: Application
    Filed: May 20, 2008
    Publication date: June 2, 2011
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Stefan Golz, Andreas Geerts
  • PROCESS FOR PREPARING METHYL METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND
    Publication number: 20110130410
    Abstract: The present invention relates to a process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate of the formula (I) and to a process for purifying the crude product of the compound of the formula (I) for use as pharmaceutically active compound, where, for purification, methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate sulphinyldimethane (1:1), i.e. a compound of the formula (II), is isolated as intermediate or is generated as intermediate in this purification process, if appropriate present in a mixture.
    Type: Application
    Filed: November 29, 2010
    Publication date: June 2, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Franz-Josef MAIS, Joachim REHSE, Winfried JOENTGEN, Konrad SIEGEL
  • SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF
    Publication number: 20110130445
    Abstract: The present application relates to novel 3-phenylpropionic acid derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders.
    Type: Application
    Filed: October 28, 2010
    Publication date: June 2, 2011
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Thomas LAMPE, Michael HAHN, Johannes-Peter STASCH, Karl-Heinz SCHLEMMER, Frank WUNDER, Sherif EL SHEIKH, Volkhart Min-Jian LI, Eva-Maria BECKER, Friederike STOLL, Andreas KNORR
  • PROCESS FOR PREPARING METHYL CARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND
    Publication number: 20110130411
    Abstract: The present invention relates to processes for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate, i.e. the compound of the formula (I) and to a process for purifying the crude product of the formula (I) for use as pharmaceutically active compound, where, for purification, methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate sulphinyldimethane (1:2) of the formula (II) is isolated as intermediate or is generated as intermediate in this purification process, if appropriate present in a mixture.
    Type: Application
    Filed: November 29, 2010
    Publication date: June 2, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Franz-Josef MAIS, Joachim REHSE, Winfried JOENTGEN, Konrad SIEGEL
  • SUBSTITUTED ARYLOXAZOLES AND THEIR USE
    Publication number: 20110130377
    Abstract: The present application relates to novel substituted aryloxazole derivatives, a method for the production thereof, the use thereof for the treatment and/or prophylaxis of diseases and the use thereof for the production of drugs for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular and metabolic disorders.
    Type: Application
    Filed: July 17, 2008
    Publication date: June 2, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Peter Nell, Walter Hübsch, Barbara Albrecht-Küpper, Jorg Keldenich, Alexandros Vakalopoulos, Frank Süssmeier, Katja Zimmermann, Dieter Lang, Daniel Meibom
  • Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof
    Publication number: 20110124665
    Abstract: The present application relates to novel, cyclically substituted furopyrimidine derivatives, methods for their production, their use for the treatment and/or prophylaxis of diseases and their use for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular diseases.
    Type: Application
    Filed: December 8, 2006
    Publication date: May 26, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Thomas Lampe, Eva-Maria Becker, Raimund Kast, Hartmut Beck, Mario Jeske, Joachim Schuhmacher, Friederike Stoll, Martina Klein, Metin Akbaba, Andreas Knorr, Johannes-Peter Stasch, Lars Bärfacker, Alexander Hillisch, Gunter Karig, Mark Meininghaus, Karl-Heinz Schlemmer, Rudolf Schohe-Loop
  • Use of radioactively labelled molecule specifically binding to ED-B fibronection in a method of treatment of Hodgkin lymphoma
    Publication number: 20110123444
    Abstract: The invention relates to the use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment for patients with Hodgkin lymphoma, in particular primary refractory Hodgkin lymphoma or recurrent Hodgkin lymphoma after chemotherapy, and for Hodgkin lymphoma patients scheduled for primary combined-modality therapy.
    Type: Application
    Filed: May 2, 2009
    Publication date: May 26, 2011
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Hans Dietrich Menssen, Jörg Pinkert
  • 1,4-DIARYL-PYRIMIDOPYRIDAZINE-2,5-DIONES AND THEIR USE
    Publication number: 20110118221
    Abstract: The present invention relates to novel 1,4-diarylpyrimido[4,5-d]pyridazine-2,5-dione derivatives, to processes for their preparation, to their use alone or in combination for the treatment and/or prevention of diseases and also to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of disorders of the lung and the cardiovascular system.
    Type: Application
    Filed: April 24, 2009
    Publication date: May 19, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Franz Von Nussbaum, Dagmar Karthaus, Martina Delbeck, Volkhart Min-Jian Li, Daniel Meibom, Klemens Lustig
  • Purification Strategy for Direct Nucleophilic Procedures
    Publication number: 20110112293
    Abstract: The present invention provides novel and advantageous processes for preparing and purifying chemical compounds such as pharmaceuticals. The processes comprise a nucleophilic substitution reaction with a moiety X wherein the leaving group L of a substrate S in the reaction is covalently attached to a purification moiety M. This concept offers a convenient and lime-saving way to purity the desired product S-X from non-reacted precursors S-L-M and by-products L-M.
    Type: Application
    Filed: April 9, 2009
    Publication date: May 12, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: John Cyr, Ananth Srinivasan, Mathias Berndt, Keith Graham, Dae Yoon Chi, Byoung Se Lee, So Young Chu, Song-Yi Lim, Sang Ju Lee, Jin-Sook Ryu, Seung Jun Oh
  • CTGF AS A BIOMARKER, THERAPEUTIC AND DIAGNOSTIC TARGET
    Publication number: 20110111394
    Abstract: The invention provides CTGF which is associated with the cardiovascular diseases and hematological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases and hematological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of CTGF as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: October 4, 2007
    Publication date: May 12, 2011
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Stefan Golz, Holger Summer, Andreas Geerts, Ulf Brüggemeier, Barbara Albrecht-Küpper, Martina Klein, Sonja Steppan, Peter Ellinghaus, Donatella D'Urso, Michael Seewald, Hendrik Milting
  • Novel [F-18]-labelled L-glutamic acid and L-glutamine derivatives (II), their use and processes for their preparation
    Publication number: 20110104057
    Abstract: What is described are the compounds and the synthesis of [F-18]-labelled L-glutamic acid, [F-18]-labelled L-glutamate, their derivatives of the formula (I) and their use.
    Type: Application
    Filed: May 13, 2009
    Publication date: May 5, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Ludger Dinkelborg, Keith Graham, Mathias Berndt, Norman Koglin, Heribert Schmitt-Willich, Matthias Friebe, Lutz Lehmann
  • DIMERIC MOLECULAR COMPLEXES
    Publication number: 20110104058
    Abstract: Dimeric molecular complexes comprising an IgE CH4 dimerization domain useful for diagnostics and therapeutics.
    Type: Application
    Filed: May 24, 2007
    Publication date: May 5, 2011
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Tara Heitner, David Light, Kirk McLean, Renate Parry, Noboru Satozawa, Douglas Schneider, Marian Seto
  • ESTRADIOL-CONTAINING DRUG DELIVERY SYSTEM
    Publication number: 20110097405
    Abstract: The present invention relates to drug delivery systems in the form of thin water-soluble films (wafers), which contain estradiol, or derivatives thereof, in low amounts. The wafers of the present invention are suitable for treating, alleviating or preventing a physical condition in a female mammal caused by insufficient endogenous levels of estrogen.
    Type: Application
    Filed: February 5, 2009
    Publication date: April 28, 2011
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Adrian Funke, Sascha General, Ildikó Terebesi, Christian Zurth, Sofia Alincic-kunz, Matthias Schäfer, Thomas Holler, Konstanze Diefenbach
  • 2-aminoethoxyacetic acid derivatives and their use
    Patent number: 7932278
    Abstract: The present application relates to novel 2-aminoethoxyacetic acid derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular thromboembolic disorders.
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: April 26, 2011
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Christian R. Thomas, Susanne Röhrig, Elisabeth Perzborn
  • SGC STIMULATORS, SGC ACTIVATORS AND COMBINATIONS THEREOF FOR THE TREATMENT OF HEARING IMPAIRMENT
    Publication number: 20110092500
    Abstract: The invention provides pharmacological compositions comprising a stimulator or activator of the soluble guanylate cyclase (sGC) either alone or in combination for the treatment of hearing impairment i.e. hearing loss and tinnitus.
    Type: Application
    Filed: April 28, 2009
    Publication date: April 21, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Peter Sandner, Johannes-Peter Stasch
  • Intermediates for the preparation of lipoxin Aanalogs
    Patent number: 7928255
    Abstract: This invention is directed to lipoxin A4 analogs of the following formula (I) and (II): wherein R1, R2, R3, R4 and R5 are described herein. These analogs are useful in treating inflammatory and autoimmune disorders in humans. These analogs are also useful in treating pulmonary or respiratory tract inflammation in humans.
    Type: Grant
    Filed: October 23, 2006
    Date of Patent: April 19, 2011
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: John G. Bauman, William Guilford, John Parkinson, Werner Skuballa, Babu Subramanyam
  • Substituted 2,3-dihydroimidazo[1,2-c]quinazoline Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis
    Publication number: 20110083984
    Abstract: This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: December 5, 2007
    Publication date: April 14, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Martin Hentemann, Jill Wood, William Scott, Martin Michels, Ann-Marie Campbell, Ann-Marie Bullion, Bruce R. Rowley, Aniko Redman
  • Injection device
    Patent number: 7909796
    Abstract: An injection device for a syringe, having a syringe body, a cannula with a needle, a plunger with a plunger rod, and an injection carriage for displacing the syringe body and the plunger, comprises at least one actuating element that acts on the injection carriage to carry out the injection procedure. The actuating element (120, 220, 320) cooperates with components which withdraw the needle (108, 208, 308) from the puncture site once the injection procedure has been completed, using a return stroke (H3) that is applied to the injection carriage. A single, targeted linear movement inserts the needle to a defined depth, injects the medicament and, once the injection has been completed, produces a return stroke which allows the needle to be withdrawn into the housing and thus out from the puncture site.
    Type: Grant
    Filed: July 23, 2004
    Date of Patent: March 22, 2011
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventor: Wilfried Weber